| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Summit Therapeutics |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Adaptimmune |
| Recipient: You |
| Company: Johnson and Johnson/Jannsen |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Merck |
| Recipient: Your Institution |
| Company: AstraZeneca/MedImmune |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Ayala |
| Recipient: Your Institution |
| Company: CUE Biopharma |
| Recipient: Your Institution |
| Company: Genentech |
| Recipient: Your Institution |
| Company: Sanofi/Aventis |
| Recipient: Your Institution |
| Company: Prelude Therapeutics |
| Recipient: Your Institution |
| Company: Adagene |
| Recipient: Your Institution |
| Company: OncoC4 |
| Recipient: Your Institution |
| Company: Seagen |
| Recipient: Your Institution |
| Company: NCCN/Lilly |
| Recipient: Your Institution |
| Company: Bayer |
| Recipient: Your Institution |
| Company: BeiGene |
| Recipient: Your Institution |
| Company: Denovo Biopharma |
| Recipient: Your Institution |
| Company: coherus |
| Recipient: Your Institution |
| Company: Rgenta |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: NCCN |
| Recipient: Your Institution |
| Company: Tempus |
| Recipient: Your Institution |
| Company: Tubulis GmbH |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|